Overview

Study to Evaluate ARD-101 in Adults With Obesity

Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.
Phase:
Phase 2
Details
Lead Sponsor:
Aardvark Therapeutics, Inc.
Collaborator:
University of California, San Diego